BriaCell Pushes Personalized Melanoma Vaccine Bria-MEL+™ Toward the Clinic
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) cleared a key genetic engineering milestone for Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate. The clinical-stage biotech engineers the candidate to recruit a patient’s own immune system against melanoma, and the milestone moves the program a step closer to the clinic.
Key Points
- BriaCell hit a genetic engineering milestone for Bria-MEL+, a personalized whole-cell melanoma immunotherapy vaccine candidate.
- A saliva test replaces custom manufacturing. The test matches each patient to a premanufactured cell line, so BriaCell avoids building a separate batch for every individual.
- The candidate builds on the Bria-OTS+ platform, which selects premanufactured cell lines through patient HLA matching.
- The pipeline keeps widening. Bria-IMT™ is in a Phase 3 metastatic breast cancer trial, while Bria-OTS™ (breast cancer) and the recently FDA-cleared Bria-PROS+™ (prostate cancer) advance alongside it.
- The target market is sizable. The American Cancer Society estimates roughly 112,000 new US melanoma cases in 2026 and about 8,510 deaths.
How Bria-MEL+ Works
Rather than manufacture a bespoke product for each patient, BriaCell premanufactures a library of treatment cell lines and then matches patients to them. A simple saliva test determines which line a given patient receives. As a result, the company delivers a personalized therapy with the logistics of an off-the-shelf one.
President and CEO William V. Williams, MD, framed the trade-off directly: “Bria-MEL+ combines advantages of personalized immunotherapy with accessibility of an off-the-shelf vaccine. Eliminating individualized manufacturing broadens access, shortens timelines, and reduces costs.”
A Platform, Not a One-Off
Bria-MEL+ derives from BriaCell’s Bria-OTS+ off-the-shelf cellular immunotherapy platform, which pairs patients with premanufactured cell lines through HLA matching. Consequently, each new indication leans on infrastructure the company has already built rather than starting from scratch.
Chief Scientific Officer Miguel A. Lopez-Lago, PhD, tied the melanoma work back to earlier results: “Building on encouraging results from our metastatic breast cancer program, we expand our pipeline with additional personalized, cell-based immunotherapy vaccine candidates, including Bria-MEL+ for melanoma.”
That expansion now spans four programs. Bria-IMT anchors the pipeline in a Phase 3 metastatic breast cancer trial. Bria-OTS targets breast cancer, and Bria-PROS+ — cleared by the FDA earlier this year — targets prostate cancer. Bria-MEL+ extends the same approach into melanoma.
Why Melanoma
Melanoma accounts for just 1% of skin cancers, yet it causes the majority of skin cancer deaths. The American Cancer Society projects approximately 112,000 new US cases in 2026 and roughly 8,510 deaths. Therefore, a therapy that reaches patients faster and at lower cost addresses a meaningful gap, particularly for patients who progress on existing checkpoint inhibitors.
About BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL; TSX: BCT)
BriaCell is an immuno-oncology-focused biotechnology company developing targeted approaches to cancer management. Learn more at briacell.com.
